Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Boston Scientific (NY: BSX )

89.42 -2.08 (-2.27%)
Streaming Delayed Price Updated: 12:02 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Boston Scientific

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Boston Scientific Highlights Trial Data For EkoSonic System For Pulmonary Embolism
Boston Scientific Corporation (NYSE: BSX) announced results for the EkoSonic Endovascular System at the Vascular InterVentional Advances (VIVA) meeting. ... 
Via Benzinga
FDA Takes Note Of Higher Risk For Women With Stroke-Preventing Implants
The FDA informed health care providers of the potential for differences in procedural outcomes between women and men undergoing implant of a left atrial appendage... 
Via Benzinga
Exposures Product Safety
Increasing Incidences of Cardiac Arrhythmias Raising Demand for Electrophysiology Medical Devices
Via FinancialNewsMedia
Boston Scientific Acquires Provider Of Thrombectomy Platform In Over $300M Deal
Boston Scientific Corporation (NYSE: BSX) has agreed to acquire Devoro Medical Inc for over 300 million. Boston Scientific has been a strategic investor in... 
Via Benzinga
Where Boston Scientific Stands With Analysts
Within the last quarter, Boston Scientific (NYSE:BSX) has ob... 
Via Benzinga
Unusual Options Activity Insight: Boston Scientific
On Tuesday, shares of Boston Scientific (NYSE:BSX) saw unusu... 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
Why Boston Scientific Shares Are Trading Higher Today
Boston Scientific (NYSE:BSX) shares are trading higher after ... 
Via Benzinga
Earnings Scheduled For July 27, 2021
Companies Reporting Before The Bell • Navios Maritime Partners (NYSE:NMM) is projected to report quarterly earnings at $2.93 per share on revenue of $146.03 million.... 
Via Benzinga
Boston Scientific Posts Colorectal Cancer Survival Data For Tumor-Targeting Microbeads
Boston Scientific Corporation (NYSE: BSX) announced that the EPOCH clinical trial of the TheraSphere Y-90 Glass Microspheres (TheraSphere treatment) met both primary... 
Via Benzinga
'Fast Money Halftime Report' Picks For September 15
On CNBC's "Fast Money Halftime Report," Karen Firestone said Charles Schwab (NYSE: SCHW) has a lot of new young traders who have larger accounts than Robinhood... 
Via Benzinga
Abbott Says Amulet Superior To Boston Scientific's Watchman In Stroke Study
Abbott Laboratories (NYSE: ABT) has announced late-breaking data from the Amulet LAA Occluder IDE trial. The head-to-head study compared Abbott's Amplatzer... 
Via Benzinga
Post Market Studies Reinforce Unfavorable Risk-Benefit Profile For Boston Scientific's Vaginal Mesh
Final results from postmarket surveillance studies of Boston Scientific Corporation's (NYSE: BSX) transvaginal mesh for pelvic organ prolapse (POP) have reinforced... 
Via Benzinga
Boston Scientific's Exalt Model B Single-Use Bronchoscope Wins FDA Approval
The FDA has given 510(k) clearance for Boston Scientific Corp's (NYSE: BSX) Exalt Model B single-use bronchoscope for use in bedside procedures within the intensive... 
Via Benzinga
Exposures Product Safety
Boston Scientific Recalls Faulty Pacemakers Due To Risk of Incorrect Transition To Safety Mode
Boston Scientific Corporation (NYSE: BSX) is recalling Ingenio family pacemakers or cardiac resynchronization therapy pacemakers (CRT-Ps) devices due to the risk of... 
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Boston Scientific Starts Trial For EkoSonic Endovascular System In Patients With Pulmonary Embolism
Boston Scientific Corporation (NYSE: BSX) began enrollment for a clinical trial of its EkoSonic endovascular system (EKOS). Boston Scientific’s HI-PEITHO... 
Via Benzinga
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
'Fast Money Halftime Report' Picks For July 30
On CNBC's "Fast Money Halftime Report," Shannon Saccocia picked salesforce.com, inc. (NYSE: CRM) as her final trade. The company is going to report earnings in few... 
Via Benzinga
Stock Market Rally Pauses Near Highs Amid Earnings From Apple, Microsoft, Tesla, Amazon, Google, Facebook
The market rally paused on the key indexes amid earnings from Apple, Tesla and Amazon. But several stocks flashed buy signals. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Boston Scientific Corp (BSX) Q2 2021 Earnings Call Transcript
BSX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Boston Scientific Earnings Top; BSX Stock Just Below Buy Point
Boston Scientific earnings and revenue beat Q2 views for the medtech giant. BSX stock rose to just below a buy point. 
Via Investor's Business Daily
Boston Scientific Earnings Exceed Expectations As Demand Picks Up, Raises FY21 Guidance
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.1 billion in Q2 of 2021, beating the estimate of $2.9 billion. Sales increased 53.6% Y/Y on a... 
Via Benzinga
Recap: Boston Scientific Q2 Earnings
Shares of Boston Scientific (NYSE:BSX) fell 1.0% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 400.00% year... 
Via Benzinga
Unusual Options Activity Insight: Boston Scientific
Boston Scientific (NYSE:BSX) shares experienced unusual options activity on Thursday. The stock price moved up to $43.24 following the option alert. Sentiment: BULLISH Option... 
Via Benzinga
Understanding Boston Scientific's Unusual Options Activity
Shares of Boston Scientific (NYSE:BSX) saw some unusual options activity on Wednesday. Following the unusual option alert, the stock price moved down to $42.7. Sentiment:... 
Via Benzinga
Stocks That Hit 52-Week Highs On Tuesday
This morning 85 companies set new 52-week highs. Noteworthy Mentions: The largest company by market cap to set a new 52-week high was Alphabet (NASDAQ:GOOG). Intec... 
Via Benzinga
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
Boston Scientific's Debt Overview
Over the past three months, shares of Boston Scientific (NYSE:BSX) rose by 12.01%. Before we understand the importance of debt, let us look at how much debt Boston... 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.